• The company’s IPO is open for subscription from 21 to 25 November 2025


• Funds of ₹75.8 crore will be used for expansion of production capacity

Mumbai, 18 November 2025: Sudeep Pharma Limited has raised Rs 563 per equity share of face value Rs 1 each for its first initial public offer. The price band has been fixed up to Rs.593. A company’s initial public offering (IPO or offer) will open for subscription on Friday, November 21, 2025 and close on Tuesday, November 25, 2025.

Investors can bid for a minimum of 25 equity shares and thereafter in multiples of 25 equity shares. Anchor Book will be on Thursday, November 20, 2025. The IPO is a combination of a fresh issue of Rs 95 crore and an offer-for-sale of 13,490,726 shares worth Rs 800 crore by the promoter and promoter group selling shareholders.

The funds of Rs 75.8 crore from this fresh issue will be for capital expenditure to purchase machinery for the company’s production line at Nandesari Facility 1 in Gujarat and for general corporate purposes. The company is a technology-led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem. The Company uses its internally developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparation and blending in an effort to innovate our operations.

‘Farmers are climate heroes’, international campaign launched by UPL in the wake of COP30

The company has established its presence in domestic and international markets in more than 100 countries, including major regions such as the United States, South America, Europe, the Middle East, Africa and Asia-Pacific. In terms of production capacity, with an annual available production capacity of 72,246 MT as of June 30, 2025, the company is one of the largest producers of food-grade iron phosphate for the infant nutrition, clinical nutrition and food and beverage sectors (Source: F&S Report). As of the same date, one of its manufacturing facilities has been approved by the United States Food and Drug Administration (USFDA) for the manufacture of mineral-based ingredients.

Sudeep Pharma’s scientific accuracy and quality have helped position us as a trusted partner to customers worldwide. The company has served more than 1,100 customers and is represented by Pfizer Inc., Intas Pharmaceuticals Ltd., Mankind Pharma Ltd., Merck Group, Alembic Pharmaceutical Ltd., Aurobindo Pharma Ltd., Cadilla Pharmaceutical Ltd., IMCD Asia Pvt. Ltd., Micro Labs Limited and Danone SA have established long-term relationships with major customers.

ICICI Securities Limited and IIFL Capital Services Limited are the book-running lead managers for this issue; and MUFG Intime India Private Limited is the Registrar of the Offer.

The offer is being made through a book-building process, wherein not more than 50 percent of the net offer is allotted to qualified institutional buyers and not more than 15 percent and 35 percent of the net offer is allotted to non-institutional bidders and retail individual bidders respectively.

Launch of ‘Elevate’ Cohort under BPCL ‘Ankur Fund’; Invitation to Green Tech, Cybersecurity Startups